|
|
Volumn 95, Issue 4, 2001, Pages 266-270
|
|
c-erbB-2 (HER-2/NEU) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients
|
|
Author keywords
Breast cancer; C erbB 2; Gene amplification; Prognosis; Protein over expression
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EPIRUBICIN;
FLUOROURACIL;
GENE PRODUCT;
HORMONE;
HORMONE RECEPTOR;
PROTEIN P185;
TAMOXIFEN;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ARTICLE;
AXILLARY LYMPH NODE;
BREAST CARCINOMA;
CANCER GRADING;
CANCER RISK;
CANCER SIZE;
CONTROLLED STUDY;
DISEASE ASSOCIATION;
FEMALE;
FOLLOW UP;
GENE AMPLIFICATION;
GENE OVEREXPRESSION;
GENETIC ANALYSIS;
HISTOPATHOLOGY;
HUMAN;
HUMAN TISSUE;
MAJOR CLINICAL STUDY;
METASTASIS;
MORTALITY;
ONCOGENE C ERB;
PARTIAL MASTECTOMY;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN EXPRESSION;
RISK FACTOR;
SOUTHERN BLOTTING;
TREATMENT OUTCOME;
BLOTTING, SOUTHERN;
BREAST NEOPLASMS;
DISEASE-FREE SURVIVAL;
FEMALE;
GENE AMPLIFICATION;
GENES, ERBB-2;
GENETIC MARKERS;
HUMANS;
MIDDLE AGED;
NEOPLASM METASTASIS;
PREDICTIVE VALUE OF TESTS;
PROGNOSIS;
PROPORTIONAL HAZARDS MODELS;
RECEPTOR, ERBB-2;
RISK;
SURVIVAL RATE;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 0035919861
PISSN: 00207136
EISSN: None
Source Type: Journal
DOI: 10.1002/1097-0215(20010720)95:4<266::AID-IJC1045>3.0.CO;2-E Document Type: Article |
|
Times cited : (41)
|
|
References (25)
|
